Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article

Searching for genes linked to birth defects

Artist’s impression of embryos.Credit: Maksim Tkachenko/iStock/Getty

Neural tube defects (NTDs) — flaws in the tube that develops into the brain and spine as the embryo develops — are the second most common birth defect following heart defects.

In northern China, nearly four out of 1,000 live births are affected by NTDs1, linked to risk factors, including insufficient folic acid in a mother’s diet, excessive alcohol consumption, pesticide and X-ray radiation exposure, and history of stillbirth. The NTD incidence is nearly four times the global average.

Geneticist and paediatrician, Zhengwei Yuan, has been conducting research at the Key Laboratory of Pediatric Congenital Anomalies of the Shengjing Hospital of China Medical University since 1996. Here his team has identified genes that may underpin NTDs, as well as developed new in utero tests and treatments.

“Our translational research projects range from embryo screening and interventions to postnatal assessment and rehabilitation,” says Yuan.

Embryonic screening

NTDs can lead to symptoms including leg paralysis, incontinence and conditions such as spina bifida and ‘anencephaly’, where parts of the brain and skull are missing. NTDs can be caused by both environmental and genetic factors, but often the precise cause of specific instances is elusive, he explains.

Geneticist Zhengwei Yuan (at right), of the Shengjing Hospital of China Medical University, strives to understand embryo development.Credit: Shengjing Hospital of China Medical University

Yuan’s team has identified several genetic factors in mice. Among these discoveries, was a link to abnormally high levels of nuclear factor I-C (NFIC) — a transcription factor that translates DNA into RNA. They also found that the high NFIC levels activate miR-200b, an RNA that helps regulate a gene called Ambra1, which regulates the breakdown of cells. This finding suggested a mechanism for the way NFIC triggers NTDs, and was published in 20222.

Yuan’s team have launched a series of nationally funded projects, unravelling many other NTD-related genes and their molecular mechanisms in animal models through advanced multi-omics technologies, says Yuan.

But, so far, “only a few NTD-related genes identified in animal models have been confirmed in human cases,” he cautions.

Diagnosis to treatment

His team is also working to make early embryonic diagnosis of NTDs and other congenital conditions a reality. At the moment, a NTD is diagnosed using ultrasound or amniocentesis, where a needle is used to remove small amounts of fluid from around the fetus.

From studies of human maternal serum, Yuan’s team has identified 24 proteins and 20 RNAs that might be able to be used as non-invasive prenatal screening markers of NTDs and other congenital conditions3. “We have combined molecular markers and machine learning to test four early-warning models for congenital malformations,” he says.

The team also wants to improve treatment of NTDs. Currently, treatment focuses mainly on tissue repair to fetal spinal tissue for life-threatening disorders, leaving the damaged nerves untreated. They are hoping to conduct preclinical studies of stem cell therapies to repair and reconstruct neurons before the birth, via microsurgery and microinjection.

Yuan’s team also actively promotes exchanges with international academics and has worked to help write national guidelines summarizing their experiences of birth defect diagnosis.

On the research side, the laboratory plans to incorporate big data technologies in observational studies across the entire embryonic development period. “We are building more specialized patient cohorts on a larger scale, and initiating more randomized and controlled studies,” says Yuan.

References

Search

Quick links